TrialClinical and translational science2023

Keverprazan, a novel potassium-competitive acid blocker: Multiple oral doses safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects.

Sufeng Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.